ClinConnect ClinConnect Logo
Search / Trial NCT02434393

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · May 4, 2015

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Depression Late Life Depression Lld Amyloid Imaging Biomarkers

ClinConnect Summary

The ADNI Depression Project is a research study aimed at understanding how late-life depression (LLD) affects thinking and memory. Researchers want to learn more about why some older adults with depression experience faster declines in their cognitive abilities. This study, which started in 2015, will involve about 120 participants, some of whom were part of the original study, and will also include new participants over the next 30 months. They will compare these individuals with around 300 people who do not have depression.

To be eligible for the study, participants should have previously taken part in related research studies. They can be on stable antidepressants or have completed therapy sessions before joining, but those taking cognitive-enhancing medications can also participate. During the study, participants will undergo several assessments, including brain scans and blood tests to gather important health information. This research can help improve our understanding of how depression impacts the brain in older adults and may lead to better treatments in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Individual participated in original Characterizing Cognitive Decline in Late Life Depression study or Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression Study.
  • Exclusion Exceptions:
  • 1. Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan.
  • 2. Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan.
  • 3. Participants taking cognitive enhancing medications will be able to enter the study.

About University Of Southern California

The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.

Locations

Pittsburgh, Pennsylvania, United States

San Francisco, California, United States

San Francisco, California, United States

Patients applied

0 patients applied

Trial Officials

Scott Mackin, PhD

Study Director

University of California, San Francisco

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials